Sign In
Buy HALO
$82.54
-0.760 (-0.91%)
At Close: Jul 31, 2026
Best Momentum Stock to Buy for September 3rd
11:01am, Wednesday, 03'rd Sep 2025
HALO, TROW and CARS made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 3, 2025.
Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year?
10:41am, Wednesday, 03'rd Sep 2025
Here is how Halozyme Therapeutics (HALO) and atai Life Sciences N.V. (ATAI) have performed compared to their sector so far this year.
Halozyme Therapeutics, Inc. (HALO) Hit a 52 Week High, Can the Run Continue?
10:15am, Wednesday, 03'rd Sep 2025
Halozyme Therapeutics (HALO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
New Strong Buy Stocks for September 3rd
07:26am, Wednesday, 03'rd Sep 2025
TDW, JRVR, HALO, SCSC and CSW have been added to the Zacks Rank #1 (Strong Buy) List on September 3, 2025.
Identify Superstar Stocks Like Halozyme with Money Flows
02:01pm, Friday, 29'th Aug 2025
Halozyme Therapeutics, Inc. (HALO) shares up 491% since first Big Money outlier inflow signal in March 2014.
Halozyme to Participate at Upcoming Investor Conferences
08:30am, Thursday, 28'th Aug 2025
SAN DIEGO , Aug. 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Tram Bui, VP of Inve
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
10:51am, Wednesday, 27'th Aug 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term
10:51am, Monday, 11'th Aug 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
After Golden Cross, Halozyme Therapeutics (HALO)'s Technical Outlook is Bright
10:56am, Friday, 08'th Aug 2025
Halozyme Therapeutics, Inc. (HALO) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, HALO's 50-day simple moving average crosse
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
10:40am, Friday, 08'th Aug 2025
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View
01:01pm, Wednesday, 06'th Aug 2025
Halozyme jumps 5.3% on second-quarter earnings and revenue beat, fueled by strong royalty growth, and a raised 2025 outlook.
Analysts Just Upgraded these Five Stocks
08:04am, Wednesday, 06'th Aug 2025
Bank of America reiterated its buy rating on Palantir with a price target of $180.
Halozyme Therapeutics, Inc. (HALO) Q2 2025 Earnings Call Transcript
05:45am, Wednesday, 06'th Aug 2025
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Helen I. Torley - President, CEO & Director Nicole LaBrosse - Senior VP & CFO
Halozyme (HALO) Q2 EPS Jumps 69%
10:26pm, Tuesday, 05'th Aug 2025
Halozyme (HALO) Q2 EPS Jumps 69%
Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics
08:00pm, Tuesday, 05'th Aug 2025
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with
